Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPI | P09923 | 1/20 | 0.56 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.56 |
| ▸ | XIAP | P98170 | 1/20 | 0.56 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.56 |
| ▸ | SLC15A1 | P46059 | 2/20 | 0.49 |
| ▸ | CPA1 | P15085 | 6/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.45 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.45 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.45 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.44 |
| ▸ | MMP2 | P08253 | 1/20 | 0.44 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29034485 | 1.00 | ALPI (0.56) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL1067685 | 0.86 | SLC7A5 (0.56) | SLC7A5HDAC8MMP2 | |
| SCHEMBL27692711 | 0.81 | CPA1 (0.45) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Phenylalanine Methyl Ester SCHEMBL27558673 | 0.81 | ALDH1A1 (0.55) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL2785098 | 0.81 | SLC7A5 (0.70) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL19618992 | 0.81 | CPA1 (0.47) | CPA1 | |
| SCHEMBL27623586 | 0.81 | CPA1 (0.47) | ALPIPKMPTGS1XIAPSLC7A5 | |
| Nitric Acid SCHEMBL27682850 | 0.80 | ALPI (0.51) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3310196 | 0.80 | PTGS2 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 | |
| SCHEMBL3310195 | 0.80 | PTGS2 (0.49) | ALPIPKMPTGS1XIAPSLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | claimed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | claimed |
| CN-119410678-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | claimed |
| CN-119410679-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | claimed |
| CN-112313336-B | Method for optimizing antibody expression | AMBRX公司 | 2024-12-03 | — | — | CN | claimed |
| CN-117924503-A | Humanized anti-Prostate Specific Membrane Antigen (PSMA) antibody drug conjugates | AMBRX公司 | 2024-04-26 | — | — | CN | claimed |
| CN-110959041-B | Methods and compositions for promoting production of proteins containing unnatural amino acids | AMBRX公司 | 2023-09-29 | — | — | CN | claimed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | claimed |
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2026-05-19 | — | — | US | disclosed |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | BICYCLETX LIMITED (GB) | 2025-02-20 | — | — | US | disclosed |
| CN-119410679-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | disclosed |
| CN-119410678-A | Method for optimizing antibody expression | AMBRX公司 | 2025-02-11 | — | — | CN | disclosed |
| US-12049520-B2 | Bicyclic peptide ligands specific for CD137 | BICYCLETX LIMITED (GB) | 2024-07-30 | — | — | US | disclosed |
| CN-117924503-A | Humanized anti-Prostate Specific Membrane Antigen (PSMA) antibody drug conjugates | AMBRX公司 | 2024-04-26 | — | — | CN | disclosed |
| WO-2002048312-A2 | BACKBONE CYCLIZED INHIBITORS OF HEAT SHOCK PROTEINS | PEPTOR LTD. (IL) | 2002-06-20 | — | — | WO | disclosed |
| WO-2001054690-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING ANTI-BETA 1 INTEGRIN COMPOUNDS AND USES | BIOGEN, INC. (US) | 2001-08-02 | — | — | WO | disclosed |
| CN-1201794-A | Process for the preparation of (1S,4R) -or (1R,4S) -4- (2-amino-6-chloro-9H-purin-9-yl) -2-cyclopentene-1-methanol or salts thereof | LONZA AG (CH) | 1998-12-16 | — | — | CN | disclosed |
| CN-1029684-C | Process for preparing dynophine derivative | EISAI CO LTD (JP) | 1995-09-06 | — | — | CN | disclosed |
| CN-1039596-A | Preparation method in conjunction with the peptide of retroviral Protease | SMITHKLINE BECKMAN CORP (US) | 1990-02-14 | — | — | CN | disclosed |
| CN-85109722-A | Process for producing Dinorfene (DYNOPHINE) derivatives | — | 1986-10-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12630588-B2 | Bicyclic peptide ligands specific for CD137 | PTMS, IL36G, HLA-A | ALPI 2514/4885PKM 4581/4885PTGS1 4223/4885 |
| US-20250059236-A1 | BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR CD137 | CD2BP2, CD40, SDC1 | ALPI 4096/4885PKM 4670/4885PTGS1 4353/4885 |
| US-12049520-B2 | Bicyclic peptide ligands specific for CD137 | CD2BP2, CD40, SDC1 | ALPI 4096/4885PKM 4670/4885PTGS1 4353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.